Patents by Inventor David Scott Carter

David Scott Carter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11040944
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: June 22, 2021
    Assignee: Curasen Therapeutics, Inc.
    Inventors: Anthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
  • Publication number: 20210101916
    Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
    Type: Application
    Filed: December 1, 2020
    Publication date: April 8, 2021
    Inventors: Tsutomu AKAMA, David Scott CARTER, Jason S. HALLADAY, Robert T. JACOBS, Yang LIU, Jacob J. PLATTNER, Yong-Kang ZHANG, Michael John WITTY
  • Patent number: 10947196
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: March 16, 2021
    Assignee: CuraSen Therapeutics, Inc.
    Inventors: Anthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
  • Publication number: 20210009531
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 14, 2021
    Applicant: Roche Palo Alto LLC
    Inventors: CHRIS ALLEN BROKA, DAVID SCOTT CARTER, MICHAEL PATRICK DILLON, RONALD CHARLES HAWLEY, ALAM JAHANGIR, CLARA JEOU JEN LIN, DANIEL WARREN PARISH
  • Publication number: 20210008071
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: September 25, 2020
    Publication date: January 14, 2021
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen BROKA, David Scott CARTER, Michael Patrick DILLON, Anthony P.D.W. FORD, Ronald Charles HAWLEY, Alam JAHANGIR, Amy Geraldine MOORE, Daniel Warren PARISH
  • Patent number: 10882872
    Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: January 5, 2021
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu Akama, David Scott Carter, Jason S. Halladay, Robert T. Jacobs, Yang Liu, Jacob J. Plattner, Yong-Kang Zhang, Michael John Witty
  • Publication number: 20200308115
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Inventors: Anthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
  • Publication number: 20200308114
    Abstract: The present disclosure is directed to chemical compounds and to the use of such compounds in the treatment of diseases associated with an adrenergic receptor.
    Type: Application
    Filed: March 26, 2020
    Publication date: October 1, 2020
    Inventors: Anthony P. Ford, Wei Chen, David Scott Carter, Jiaxin Yu
  • Publication number: 20200115347
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: December 11, 2019
    Publication date: April 16, 2020
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Patent number: 10562921
    Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: February 18, 2020
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu Akama, David Scott Carter, Jason S. Halladay, Robert T. Jacobs, Yang Liu, Jacob J. Plattner, Yong-Kang Zhang, Michael John Witty
  • Publication number: 20200017531
    Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
    Type: Application
    Filed: September 24, 2019
    Publication date: January 16, 2020
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu AKAMA, David Scott CARTER, Jason S. HALLADAY, Robert T. JACOBS, Yang LIU, Jacob J. PLATTNER, Yong-Kang ZHANG, Michael John WITTY
  • Publication number: 20190270713
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R1 and R8 are as defined herein.
    Type: Application
    Filed: May 22, 2019
    Publication date: September 5, 2019
    Applicant: Roche Palo Alto LLC
    Inventors: CHRIS ALLEN BROKA, DAVID SCOTT CARTER, MICHAEL PATRICK DILLON, RONALD CHARLES HAWLEY, ALAM JAHANGIR, CLARA JEOU JEN LIN, DANIEL WARREN PARISH
  • Publication number: 20190016688
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: August 9, 2018
    Publication date: January 17, 2019
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Publication number: 20180311240
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen BROKA, David Scott CARTER, Michael Patrick DILLON, Anthony P.D.W. FORD, Ronald Charles HAWLEY, Alam JAHANGIR, Amy Geraldine MOORE, Daniel Warren PARISH
  • Publication number: 20180141919
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: December 14, 2017
    Publication date: May 24, 2018
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Publication number: 20170327519
    Abstract: The present invention provides oxaborole ester compounds and compositions thereof which are useful to treat diseases associated with parasites, such as Chagas Disease and African Animal Trypanosomosis.
    Type: Application
    Filed: May 9, 2017
    Publication date: November 16, 2017
    Applicant: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu AKAMA, David Scott CARTER, Jason S. HALLADAY, Robert T. JACOBS, Yang LIU, Jacob J. PLATTNER, Yong-Kang ZHANG, Michael John WITTY
  • Publication number: 20170096404
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein X is O, D, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Patent number: 9556127
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: January 31, 2017
    Assignee: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish
  • Publication number: 20160271131
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: June 1, 2016
    Publication date: September 22, 2016
    Applicant: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Anthony P.D.W. Ford, Ronald Charles Hawley, Alam Jahangir, Amy Geraldine Moore, Daniel Warren Parish
  • Publication number: 20140357629
    Abstract: Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: August 6, 2014
    Publication date: December 4, 2014
    Applicant: ROCHE PALO ALTO LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Ronald Charles Hawley, Alam Jahangir, Clara Jeou Jen Lin, Daniel Warren Parish